Phosphorus Attached Directly Or Indirectly To Morpholine Ring By Nonionic Bonding Patents (Class 544/157)
  • Patent number: 9346841
    Abstract: Methods for isolating 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine (compound 16): a method for preparing, in high diastereomeric purity, intermediate compounds 13 and 15: and a method for preparing intermediate compound 12: 9-{(R)-2-[((S)-{[(S)-1-(isopropoxycarbonyl)ethyl]amino}phenoxyphosphinyl)methoxy]propyl}adenine has anti-viral properties.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: May 24, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Denise A. Colby, Andrew Anthony Martins, Benjamin James Roberts, Robert William Scott, Nicole S. White
  • Patent number: 9029371
    Abstract: The present invention relates to bisaryl (thio)morpholine derivatives of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof, with the proviso that the derivative of formula (I) is not 2-[4-(4-chlorophenoxy)-2-chlorophenyl]-4 -morpholineethanol. The compounds of the invention have affinity to S1 Preceptors and may be used in the treatment, alleviation or prevention of S1 Preceptor mediated diseases and conditions.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: May 12, 2015
    Assignee: Abbvie B.V.
    Inventors: Wouter I. Iwema Bakker, Raymond Bronger
  • Publication number: 20140221645
    Abstract: N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, N2-phosphinyl amidinate metal salt complexes are described. Methods for making N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N2-phosphinyl amidine metal salt complexes and N2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.
    Type: Application
    Filed: January 31, 2014
    Publication date: August 7, 2014
    Applicant: CHEVRON PHILLIPS CHEMICAL COMPANY LP
    Inventors: Orson L. Sydora, Michael Carney, Brooke L. Small, Jeffery C. Gee, Steven Hutchison
  • Publication number: 20140199600
    Abstract: The present invention provides a nonaqueous electrolyte solution, which can improve flame retardancy and ameliorate performances of a battery without deteriorating the basic battery performance as far as possible, and a secondary battery. The nonaqueous electrolyte solution is a nonaqueous electrolyte solution for a secondary battery that contains metal salts including ions of metals belonging to group 1 or 2 of the periodic table and a specific cyclic compound having phosphorus and nitrogen atoms in a non-protonic solvent. The non-protonic solvent is a solvent that contains at least one kind of carboxylic acid ester compound and carbonic acid ester compound, and a ratio (MPN/Ms) between a mass (Ms) of the non-protonic solvent containing the metal salts and a mass (MPN) of the cyclic compound is 0.01 to 1.
    Type: Application
    Filed: March 18, 2014
    Publication date: July 17, 2014
    Applicant: FUJIFILM CORPORATION
    Inventors: Toshihiko YAWATA, Ikuo KINOSHITA
  • Publication number: 20140088303
    Abstract: Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicants: Sekisui Medical Co., Ltd., National University Corporation Nagoya University
    Inventors: Kazuaki ISHIHARA, Manabu HATANO, Takashi MIYAMOTO
  • Patent number: 8680003
    Abstract: N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, N2-phosphinyl amidinate metal salt complexes are described. Methods for making N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N2-phosphinyl amidine metal salt complexes and N2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: March 25, 2014
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Orson L. Sydora, Michael Carney, Brooke L. Small, Jeffery C. Gee, Steven Hutchison
  • Patent number: 8624024
    Abstract: Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: January 7, 2014
    Assignees: National University Corporation Nagoya University, Sekisui Medical Co., Ltd.
    Inventors: Kazuaki Ishihara, Manabu Hatano, Takashi Miyamoto
  • Patent number: 8518913
    Abstract: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Haiqing Yuan, Richard I. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8338593
    Abstract: The present application provides for a compound of Formula (I) or (II): or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods that include the administration of such compounds with at least one additional active agent.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: December 25, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Lee S. Chong, Manoj C. Desai, Brian Gallagher, Michael Graupe, Randall L. Halcomb, Hong Yang, Jennifer R. Zhang
  • Publication number: 20120309965
    Abstract: N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, N2-phosphinyl amidinate metal salt complexes are described. Methods for making N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes are also disclosed. Catalyst systems utilizing the N2-phosphinyl amidine metal salt complexes and N2-phosphinyl amidinate metal salt complexes are also disclosed along with the use of the N2-phosphinyl amidine compounds, N2-phosphinyl amidinates, N2-phosphinyl amidine metal salt complexes, and N2-phosphinyl amidinate metal salt complexes for the oligomerization and/or polymerization of olefins.
    Type: Application
    Filed: December 29, 2010
    Publication date: December 6, 2012
    Applicant: CHEVRON PHILLIPS CHEMICAL COMPANY LP
    Inventors: Orson L. Sydora, Michael Carney, Brooke L. Small, Jeffery C. Gee, Steven Hutchison
  • Publication number: 20120220552
    Abstract: The present disclosure relates to (thio)morpholine derivatives of the formula (I) wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino, —SO2-(1-4C)alkyl, —CO-(1-4C)alkyl, —CO—O-(1-4C)alkyl, —NH—CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from —
    Type: Application
    Filed: August 27, 2010
    Publication date: August 30, 2012
    Inventors: Wouter I. Iwema Bakker, Hein K.A.C. Coolen, Axel Stoit, Harmen Mons, Eric Ronken, Elizabeth Van Der Kam, Jurjen Frankena
  • Patent number: 8252874
    Abstract: The present invention relates to ligands and catalyst systems and a process for the simultaneous trimerization and tetramerization of olefinic monomers using said ligands, the ligands having the general formula (I): (R1)2P—P(R1)m(R2)n?N(R3)??(I) wherein R3 is selected from hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group, a heterohydrocarbyl group, a substituted heterohydrocarbyl group, a silyl group or derivative thereof; the R1 groups are independently selected from an optionally substituted aromatic group bearing a polar substituent on at least one of the ortho-positions; and the R2 groups are independently selected from hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl and substituted heterohydrocarbyl groups with the proviso that when the group is aromatic it does not contain a polar substituent at any of the ortho-positions; with the proviso that m is 0 or 1, n is 1 or 2 and the total of m+n is 2.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: August 28, 2012
    Assignee: Shell Oil Company
    Inventors: Eric Johannes Maria De Boer, Harry Van Der Heijden, Quoc An On, Johan Paul Smit, Arie Van Zon
  • Publication number: 20120214988
    Abstract: Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 23, 2012
    Applicants: Sekisui Medical Co., Ltd., National University Corporation Nagoya University
    Inventors: Kazuaki ISHIHARA, Manabu Hatano, Takashi Miyamoto
  • Publication number: 20120157413
    Abstract: The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Application
    Filed: December 9, 2011
    Publication date: June 21, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard I. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 8192753
    Abstract: The invention suggests a pH-sensitive cationic lipid with a pKa value between 3.5 and 8, according to the general formula cation-spacer-Y-spacer-X-lipid, wherein Y and X represent linking groups. Furthermore, liposomes are described, which liposomes include said optionally cationic lipids.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: June 5, 2012
    Assignee: Marina Biotech, Inc.
    Inventors: Frank Essler, Steffen Panzner, Gerold Endert
  • Publication number: 20120065169
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: May 27, 2011
    Publication date: March 15, 2012
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Publication number: 20100048866
    Abstract: Water soluble reagents and methods for the formation of an amide bond between a phosphinothioester and an azide in an aqueous medium. The phosphinothioester is generated using a water-soluble phosphinothiol reagent. This reaction allows formation of an amide bond between a wide variety of chemical species including amino acids, peptides or protein fragments in an aqueous solution. Of particular interest, this reaction allows for the formation of an amide bond in a physiological setting. In a specific embodiment, this invention provides reagents and methods for peptide ligation in an aqueous medium. The reaction eliminates the need for a cysteine residue and is traceless leaving no residual atoms in the ligated peptide product.
    Type: Application
    Filed: August 24, 2009
    Publication date: February 25, 2010
    Inventors: Ronald T. Raines, Annie Tam, Matthew B. Soellner
  • Publication number: 20090274972
    Abstract: An electrostatic-image-developing toner includes a phosphonic acid based sequestering agent.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 5, 2009
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Shuji SATO, Eisuke IWAZAKI, Atsushi SUGAWARA, Masanobu NINOMIYA, Hiroshi NAKAZAWA
  • Publication number: 20090170813
    Abstract: Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, ?, or a ?, g-cyclic amino acid; .R1 is H or R, R being an hydroxy or a carboxy protecting group; .Z is H or an amino protecting group R?, benzyl oxycarbonyl, benzyl or benzyl substituted; .E is H or a C1-C3 alkyl, aryl, an hydrophobic group; .
    Type: Application
    Filed: October 18, 2006
    Publication date: July 2, 2009
    Inventors: Francine Acher, Chelliah Selvam, Nicolas Triballeau, Jean-Philippe Pin, Hugues-Oliver Bertrand
  • Publication number: 20090069517
    Abstract: The present invention relates to ligands and catalyst systems and a process for the simultaneous trimerization and tetramerization of olefinic monomers using said ligands, the ligands having the general formula (I): (R1)2P—P(R1)m(R2)n?N(R3)??(I) wherein R3 is selected from hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group, a heterohydrocarbyl group, a substituted heterohydrocarbyl group, a silyl group or derivative thereof; the R1 groups are independently selected from an optionally substituted aromatic group bearing a polar substituent on at least one of the ortho-positions; and the R2 groups are independently selected from hydrocarbyl, substituted hydrocarbyl, heterohydrocarbyl and substituted heterohydrocarbyl groups with the proviso that when the group is aromatic it does not contain a polar substituent at any of the ortho-positions; with the proviso that m is 0 or 1, n is 1 or 2 and the total of m+n is 2.
    Type: Application
    Filed: December 20, 2007
    Publication date: March 12, 2009
    Inventors: Eric Johannes Maria DE BOER, Harry Van Der Heijden, Quoc An On, Johan Paul Smit, Arie Van Zon
  • Patent number: 7468359
    Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: December 23, 2008
    Assignee: Yissum Research Develpment Company of the Hebrew University of Jerusalem
    Inventors: Eli Breuer, Reuven Reich, Claudio Salomon
  • Patent number: 7427618
    Abstract: Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: September 23, 2008
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz, Christoph van Amsterdam
  • Patent number: 7268124
    Abstract: The invention provides novel pyrophosphate synthase inhibitors of formula I as well as compositions comprising such inhibitors and methods for their use.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: September 11, 2007
    Assignee: University of Iowa Research Foundation
    Inventors: David F. Wiemer, Raymond J. Hohl
  • Patent number: 7077976
    Abstract: The invention is a water treatment composition comprising at least one phosphonamide and blends thereof and a method to treat water. As phosphonamides are generally odorless, and typically solids, phosphonamide and phosphonamide blend compositions are generally odorless, conveniently processed and manufactured, and safely used without risks of exposure to odors and vapors associated with the corresponding amines. Advantageously, phosphonamides blended with amino-phosphate esters provide useful treatment compositions. The inventive compositions are generally used to treat water contained in water flow systems such as boilers and cooling towers.
    Type: Grant
    Filed: October 25, 2005
    Date of Patent: July 18, 2006
    Assignee: JohnsonDiversey, Inc.
    Inventors: Lyle Steimel, James Emerson, Sue Ann Balow
  • Publication number: 20040266731
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2003
    Publication date: December 30, 2004
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Publication number: 20040214798
    Abstract: The present invention relates to nitroaryl-substituted phosphoramide prodrug compounds and methods of producing the same for use in targeting and inhibiting undesirable cell growth or proliferation.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 28, 2004
    Inventor: Longqin Hu
  • Publication number: 20040198701
    Abstract: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
    Type: Application
    Filed: March 10, 2004
    Publication date: October 7, 2004
    Inventors: Xavier Billot, John Colucci, Yongxin Han, Marie-Claire Wilson, Robert N. Young
  • Patent number: 6800659
    Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: October 5, 2004
    Assignee: HSC Research and Development Limited Partnership
    Inventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
  • Publication number: 20040162426
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: February 13, 2004
    Publication date: August 19, 2004
    Inventors: Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue, Jingwu Duan, Gregory Ott, Lihua Chen, Carl Decicco
  • Patent number: 6743798
    Abstract: The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3 and A are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.
    Type: Grant
    Filed: April 11, 2001
    Date of Patent: June 1, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Alexander Straub, Achim Feurer, Cristina Alonso-Alija, Johannes-Peter Stasch, Elisabeth Perzborn, Joachim Hütter, Klaus Dembowsky, Elke Stahl
  • Patent number: 6737416
    Abstract: A compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof: wherein R1 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like; R2 and R3 represent hydrogen atom, an alkyl group, a substituted alkyl group, an alkoxyl group and the like; X represents —CH2—, —O—, or —NH—; A represents the following group (II): [in which R7 and R8 represent hydrogen atom, an alkyl group, an acyl group, an alkoxycarbonyl group and the like; R9 and R10 represents hydrogen atom, a halogen atom, hydroxyl group, phenyl group, an alkyl group and the like] and the like; and E represents hydrogen atom and the like, which has inhibitory activity against carboxypeptidase B and is useful for therapeutic and/or preventive treatment of a thrombotic disease.
    Type: Grant
    Filed: October 7, 2002
    Date of Patent: May 18, 2004
    Assignee: Meiji Seika Kaisha Ltd.
    Inventors: Kenichi Fushihara, Chika Kikuchi, Tetsuya Matsushima, Kenichi Kanemoto, Eriko Satoh, Takehiro Yamamoto, Kokichi Suzuki
  • Publication number: 20040029723
    Abstract: The present invention relates to compounds of the formula 1
    Type: Application
    Filed: August 1, 2003
    Publication date: February 12, 2004
    Applicant: Clariant GmbH
    Inventors: Berthold Schiemenz, Thomas Wessel, Ralf Pfirmann
  • Publication number: 20030232742
    Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.
    Type: Application
    Filed: November 9, 2001
    Publication date: December 18, 2003
    Inventors: Stefan Peters, Dietmar Leipert, Christian Eickmeier, John Edward Park, Martin Lenter, Pilar Garin-Chesa, Juergen Mack
  • Publication number: 20030139597
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: 1
    Type: Application
    Filed: June 20, 2002
    Publication date: July 24, 2003
    Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
  • Publication number: 20030134827
    Abstract: The present application describes novel lactams and derivatives thereof of formula I: 1
    Type: Application
    Filed: March 12, 2002
    Publication date: July 17, 2003
    Inventors: Jingwu Duan, Carl P. Decicco, Zelda R. Wasserman, Thomas P. Maduskuie
  • Publication number: 20030130186
    Abstract: This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.
    Type: Application
    Filed: July 22, 2002
    Publication date: July 10, 2003
    Inventors: Chandra Vargeese, Jasenka Matulic-Adamic, Alexander Karpeisky, Leonid Beigelman, Lawrence Blatt, Shawn Zinnen
  • Patent number: 6576161
    Abstract: The present invention relates to polyphosphate ester morpholides, compositions comprising mixtures thereof and thermoplastic resin compositions containing the polyphosphate ester morpholide composition as a flame retardant. The flame retardant compositions comprise mixtures of polyphosphate ester morpholides which are represented by the following general formula I: in which X is 1 or 2; R1 is a C6-C20 aryl group, an alkyl substituted C6-C20 aryl group or a derivative thereof; R2 is a C6-C30 arylene group, an alkyl substituted C6-C30 arylene group or a derivative thereof; n is the average number of morpholide repeating units, m is the average number of R1 repeating units, and n+m is 1 to 5. In accordance with the present invention, it is possible to provide a flame retardant thermoplastic resin compositions having improved flame retardancy even when small amounts of the flame retardant are used.
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: June 10, 2003
    Assignee: Cheil Industries, Inc.
    Inventors: Jong-Cheol Lim, Kyung-Hoon Seo, Sam-Joo Yang
  • Publication number: 20030096737
    Abstract: The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor- (IGIF), interferon-&ggr;- (“IFN-&ggr;”), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention.
    Type: Application
    Filed: April 19, 2002
    Publication date: May 22, 2003
    Inventors: Anita Diu-Hercend, Julian Golec, Thierry Hercend, Ronald Knegtel, Paul Lang, Andrew Miller, Karen Miller, Michael Mortimore, Peter Weber
  • Publication number: 20030069418
    Abstract: One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.
    Type: Application
    Filed: April 11, 2002
    Publication date: April 10, 2003
    Inventors: Brian M. Aquila, James R. Hauske, Liming Shao
  • Publication number: 20030065176
    Abstract: The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a pharmaceutically acceptable salt, a prodrug, a hydrate, a solvate or an isomer thereof, which are inhibitors of coagulation enzyme, factor Xa (FXa). The present invention also relates to a pharmaceutical composition containing the compound, and a method of using the same as an anticoagulant agent for treatment and prevention of thrombosis disorders.
    Type: Application
    Filed: July 24, 2002
    Publication date: April 3, 2003
    Inventors: Myung-Gyun Kang, Doo-Hee Park, Oh-Hwan Kwon, Eunice Eun-Kyeong Kim, Kwang-Yeon Hwang, Yong-Seok Heo, Tae-Kyo Park, Tae-Hee Lee, Kwang-Yul Moon, Jong-Woo Park, Hye-Kyung Chang, Sang-Koo Lee, Sun-Hwa Lee, Su-Kyung Park, Sung-Hack Lee, Hae-Dong Park
  • Publication number: 20030064963
    Abstract: Disclosed is a phenyl boronic acid compound represented by Structural Formula (I): 1
    Type: Application
    Filed: June 27, 2002
    Publication date: April 3, 2003
    Applicant: GelTex Pharmaceuticals, Inc.
    Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, Pradeep K. Dhal, Chad Cori Huval, Xinhua Li
  • Publication number: 20030045713
    Abstract: The invention relates to the preparation and use as catalysts of diphosphines of the formula (I) 1
    Type: Application
    Filed: August 15, 2002
    Publication date: March 6, 2003
    Inventors: Birgit Driessen-Holscher, Joachim Kralik, Inga Ritzkopf, Christian Steffens, Guido Giffels, Claus Dreisbach, Thomas Prinz, Walter Lange
  • Publication number: 20030032803
    Abstract: The present application describes novel amides and derivatives thereof of formula 1
    Type: Application
    Filed: February 12, 2002
    Publication date: February 13, 2003
    Inventors: Jingwu Duan, Carl P. Decicco, David J. Nelson, Chu-Biao Xue
  • Publication number: 20020177706
    Abstract: Novel cyclo azaphospha hydrocarbons according to formula I 1
    Type: Application
    Filed: April 11, 2002
    Publication date: November 28, 2002
    Inventors: Thomas Hoyer, Morten Dahl Sorensen
  • Publication number: 20020128208
    Abstract: The disclosed invention is a composition agonists and/or antagonists of V2, V1a or both receptors, in a host, including animals, and especially humans, using a small molecule or its pharmaceutically acceptable salt or prodrug.
    Type: Application
    Filed: December 17, 2001
    Publication date: September 12, 2002
    Inventors: James P. Snyder, Dennis C. Liotta, Hariharan Venkatesan, Minmin Wang, Matthew C. Davis
  • Publication number: 20020013297
    Abstract: The present invention describes novel halogenated triphenylethylene derivatives, or pharmaceutically acceptable prodrug or salt forms thereof, as selective estrogen receptor modulators for the treatment of and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as methods for making the compounds and pharmaceutical compositions of this invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 31, 2002
    Inventors: Robert F. Kaltenbach III, George L. Trainor
  • Publication number: 20020004496
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 10, 2002
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Patent number: 6235220
    Abstract: The invention concerns compositions for manufacturing composite materials containing a polyaniline. These compositions are formed by a solution in a solvent such as m-cresol of the following constituents: a) a conductive polyaniline protonated by means of a protonation agent able to promote the dissolution of the polyaniline in the solvent, for example phenylphosphonic acid, b) an insulating polymer chosen for example from amongst the cellulosic polymers and polyvinyl chlorides such as cellulose acetate, and c) an insulating plasticiser such as a mixture of dimethyl phthalate, diethyl phthalate and triphenyl phosphate. By pouring this solution and evaporating the solvent, it is possible to obtain a flexible film of conductive composite material having good electrical and mechanical properties.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: May 22, 2001
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Adam Pron, Yann-Florent Nicolau, Maxime Nechtschein, Françoise Genoud
  • Patent number: 5962437
    Abstract: A method of treating viral infections, and in particular HIV-1, hepatitis B virus and herpes viruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: October 5, 1999
    Assignee: Wake Forest University
    Inventors: Louis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq
  • Patent number: 5962440
    Abstract: Novel cyclic phosphonate ester inhibitors of MTP are provided which have the structure ##STR1## wherein R.sup.2, L.sup.2, A, B, L.sup.1, R.sup.1 and R.sup.5a are as set out herein. These compounds are useful in lowering serum cholesterol and triglycerides.
    Type: Grant
    Filed: October 20, 1998
    Date of Patent: October 5, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventor: Richard B. Sulsky